

		EMLc	ATC codes: L01DB01
Indication	Kaposi sarcoma of unspecified primary site	ICD11 code: 2C27.Z	
INN	Doxorubicin		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection ; 50 mg in vial (hydrochloride) powder for injection ; 2 mg per mL in 5 mL vial (hydrochloride) ; 2 mg per mL in 25 mL vial (hydrochloride)		
EML status history	First added in 2015 (TRS 994) Changed in 2019 (TRS 1021) Changed in 2023 (TRS 1049)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents.</a> 		
Tags	<span>Cancer</span>		
Wikipedia	<a href="#">Doxorubicin</a> 		
DrugBank	<a href="#">Doxorubicin</a> 		

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose forms of doxorubicin (2 mg/mL (hydrochloride) in 5 mL, 25 mL vial) to the EML and EMLc.

